ContraVir Pharmaceuticals Announces Participation at the 20th Annual Global Investment Conference in New York City September ...
30 August 2018 - 11:00PM
ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical
company focused on the development and commercialization of
therapeutic drugs for the treatment of hepatitis B virus (HBV),
announced today it will be featured as a presenting company at the
20th Annual Rodman & Renshaw Global Investment Conference,
sponsored by H.C. Wainwright & Co., LLC. The conference is
being held September 4-6, at the St. Regis New York Hotel in New
York City.
Theresa Matkovits, Chief Operating Officer of ContraVir, will
provide an overview of the company’s business during the live
presentation and will be available to participate in one-on-one
meetings with investors who are registered to attend the
conference.
If you are an institutional investor, and would like to attend
the company’s presentation, please click on the following link
(www.rodmanevents.com ) to register for the conference. Once
your registration is confirmed, you will be prompted to log into
the conference website to request a one-on-one meeting with the
company.
Event: 20th Annual Rodman & Renshaw
Global Investment Conference, sponsored by H.C. Wainwright &
Co., LLC
Date: September 6, 2018
Time: 3:00PM (Eastern Time)
Location: Louis XVI A (2nd floor); St.
Regis New York Hotel in New York City
About ContraVir Pharmaceuticals ContraVir is a
biopharmaceutical company focused on the development and
commercialization of targeted antiviral therapies with a specific
focus on developing a potentially curative oral therapy for
hepatitis B virus (HBV). The company is developing two novel
anti-HBV compounds with complementary mechanisms of action. TXL™, a
direct acting antiviral (DAA) nucleotide analog lipid prodrug of
tenofovir (TFV), is designed to deliver higher hepatic
intracellular concentrations of the active tenofovir species
(tenofovir diphosphate) while reducing concentrations of tenofovir
outside the liver, causing fewer off-target toxicities and
side-effects. CRV431, the other anti-HBV compound, is a
host-targeting antiviral (HTA) next-generation cyclophilin
inhibitor with a novel chemical structure that optimizes the
selective index against HBV. In vitro and in
vivo studies have thus far demonstrated that CRV431 reduces
HBV DNA and other viral proteins, including surface antigen
(HBsAg), while offering additional benefits to mitigate liver
disease. For more information, please
visit www.contravir.com.
For further information, please contact: Sharen
Pyatetskaya Director of Investor Relationssp@contravir.com; +1
(732) 902-4028
Contravir Pharmaceuticals Inc (NASDAQ:CTRV)
Historical Stock Chart
From Apr 2024 to May 2024
Contravir Pharmaceuticals Inc (NASDAQ:CTRV)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Contravir Pharmaceuticals (MM) (NASDAQ): 0 recent articles
More News Articles